financetom
Business
financetom
/
Business
/
Realme launches its first 5G smartphone in India
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Realme launches its first 5G smartphone in India
Feb 25, 2020 12:19 AM

Chinese smartphone maker Realme on Monday launched its first 5G smartphone titled 'X50 Pro 5G' in India, starting from Rs 37,999. The smartphone will be available in two colours and three variants -- Rs 37,999 (6GB+128GB), Rs 39,999 (8GB+128GB) and Rs 44,999 (12GB+256GB) -- on Flipkart and realme.com from 6 pm on Monday.

"We are proud to unveil India's first 5G, super-fast, performance-driven smartphone -- Realme X50 Pro 5G. Sporting best in class performance, design and quality, the Realme X50 Pro 5G is a trendsetter for the future and is our ultimate flagship," Madhav Sheth, CEO, Realme India told reporters here.

The smartphone is equipped with a 6.44-inch Super-AMOLED display which offers an aspect ratio of 20:9, with up to 92 per cent screen-to-body ratio.

The device has a 90Hz refresh rate display. At the same time, it has a 180Hz sampling rate which improves the touchscreen sensitivity and smoothness while playing games.

The phone is powered by Qualcomm Snapdragon 865 processor paired with Adreno 650 GPU and shipped with a brand new realme UI based on Android 10,

The smartphone features 64MP quad camera on the rear and dual camera on the front, with a variety of tech-trendy functions upgraded.

Other rear cameras include a 12MP telephoto camera with upto 20X zoom, an 8MP wide-angle camera, and a 2MP portrait sensor.

The device accommodates ultra-wide-angle dual camera on the front, including the main lens with a 32MP Sony IMX616 sensor and an f/2.0 aperture, as well as the 8MP ultra-wide-angle lens with an f/2.2 aperture and a 105-degree field-of-view.

Both cameras support selfies in HDR and Nightscape mode.

In terms of video recording, ultra-wide-angle video shooting, UIS super video stabilization, selfie portrait beauty-cam and blurring the background in portrait videos are all available.

Additionally, the device houses a 4200mAh dual-cell battery and will come with flash-charging technology - 65W SuperDart.

First Published:Feb 25, 2020 9:19 AM IST

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Essential Properties Realty Trust Promotes Max Jenkins to COO
Essential Properties Realty Trust Promotes Max Jenkins to COO
Mar 27, 2025
04:53 PM EDT, 03/27/2025 (MT Newswires) -- Essential Properties Realty Trust ( EPRT ) said late Thursday that Max Jenkins has been promoted to chief operating officer. The company also said it promoted AJ Peil and Robert Salisbury to chief investment officer and head of corporate finance and strategy, respectively. ...
EXPLAINER-New creditors' battle emerges in Citgo auction reboot
EXPLAINER-New creditors' battle emerges in Citgo auction reboot
Mar 27, 2025
* New bidding round starts after year-long auction ended in shambles * Creditors' dispute over minimum bid to add more delays in 8-year-old case * Bondholders pact released at Gold Reserve ( GDRZF )-consortium's request * Bids by Venezuela-linked creditors turn auction into creditors game By Marianna Parraga HOUSTON, March 27 (Reuters) - A U.S. federal judge trying to move...
Braze Fiscal Q4 Swings to Profit, Revenue Rises; Shares Gain After Hours
Braze Fiscal Q4 Swings to Profit, Revenue Rises; Shares Gain After Hours
Mar 27, 2025
04:53 PM EDT, 03/27/2025 (MT Newswires) -- Braze (BRZE) reported fiscal Q4 non-GAAP earnings Thursday of $0.12 per diluted share, compared with a loss of $0.04 a year earlier. Analysts polled by FactSet expected earnings of $0.05. Revenue in the three months ended Jan. 31 rose to $160.4 million from $131 million a year earlier. Analysts surveyed by FactSet expected...
Crinetics Pharmaceuticals Says EMA Validates Marketing Authorization Application for Acromegaly Drug
Crinetics Pharmaceuticals Says EMA Validates Marketing Authorization Application for Acromegaly Drug
Mar 27, 2025
04:46 PM EDT, 03/27/2025 (MT Newswires) -- Crinetics Pharmaceuticals ( CRNX ) said Thursday that the European Medicines Agency has validated its marketing authorization application for paltusotine, an oral treatment for endocrine disorder acromegaly. The marketing authorization application will now undergo review by the Committee for Medicinal Products for Human Use. This submission is supported by 18 clinical trials, including...
Copyright 2023-2025 - www.financetom.com All Rights Reserved